TOPIVERT PHARMA LTD has a total of 29 patent applications. It decreased the IP activity by 71.0%. Its first patent ever was published in 2012. It filed its patents most often in United States, EPO (European Patent Office) and Canada. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and machines are HELSINN HEALTHCARE SA, SHANGHAI ZHANGJIANG TRADITIONAL CHINESE MEDICINE MODERN PHARMACEUTICAL PREPARATION TECHNOLOGY ENGINE and BIOTHERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 8 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | Canada | 4 | |
#4 | United Kingdom | 3 | |
#5 | Mexico | 3 | |
#6 | WIPO (World Intellectual Property Organization) | 3 | |
#7 | Brazil | 1 | |
#8 | Republic of Korea | 1 | |
#9 | Uruguay | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Machines |
# | Name | Total Patents |
---|---|---|
#1 | Fyfe Matthew Colin Thor | 22 |
#2 | Thom Stephen Malcolm | 8 |
#3 | Baker Thomas Matthew | 3 |
#4 | Stephen Malcolm Thom | 2 |
#5 | Onions Stuart Thomas | 2 |
#6 | King-Underwood John | 2 |
#7 | Matthew Colin Thor Fyfe | 2 |
#8 | Hasimbegovic Vedran | 2 |
#9 | Meghani Premji | 2 |
#10 | Sambrook-Smith Colin | 2 |
Publication | Filing date | Title |
---|---|---|
US2018319791A1 | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors | |
WO2017077288A1 | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors | |
GB201519381D0 | Kinase inhibitors | |
GB201519382D0 | Kinase inhibitors | |
EP2981534A1 | Kinase inhibitors based upon n-alkyl pyrazoles | |
GB201220684D0 | New compounds |